Theravance Biopharma Files 8-K Report

Ticker: TBPH · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1583107

Theravance Biopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTheravance Biopharma, Inc. (TBPH)
Form Type8-K
Filed DateDec 8, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory-update

TL;DR

Theravance Biopharma filed an 8-K on Dec 8, 2025. Standard reporting.

AI Summary

On December 8, 2025, Theravance Biopharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." Specific details regarding material events or financial updates are not elaborated upon in the provided text, but the filing indicates a standard reporting activity.

Why It Matters

This filing indicates Theravance Biopharma is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report without immediate disclosed material events, suggesting low immediate risk.

Key Players & Entities

  • Theravance Biopharma, Inc. (company) — Registrant
  • December 8, 2025 (date) — Date of Report
  • 001-36033 (other) — Commission File Number
  • 98-1226628 (other) — I.R.S. Employer Identification Number
  • 901 Gateway Boulevard South San Francisco, CA 94080 (address) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The filing is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating "Other Events" and "Financial Statements and Exhibits."

When was this 8-K report filed?

The report was filed on December 8, 2025.

What is Theravance Biopharma, Inc.'s Commission File Number?

Theravance Biopharma, Inc.'s Commission File Number is 001-36033.

Where are Theravance Biopharma's principal executive offices located?

The principal executive offices are located at 901 Gateway Boulevard South San Francisco, CA 94080.

What is the company's state of incorporation?

The company's state of incorporation is Cayman Islands.

Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-12-08 06:29:42

Key Financial Figures

  • $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke

Filing Documents

01 Other Events

Item 8.01 Other Events. Ampreloxetine KOL Event for Investors On December 8, 2025, Theravance Biopharma, Inc. (the "Company") is holding a virtual key opinion leader (KOL) investor event. A copy of materials that will be presented during the event is furnished as Exhibit 99.1 to this Current Report. 2026 Annual General Meeting of Shareholders The Company will hold its 2026 Annual General Meeting of Shareholders on June 12, 2026, in Dublin, Ireland. Further information regarding the Annual General Meeting will be provided in the Company's proxy materials, which will be filed with the SEC and made available to shareholders prior to the Annual General Meeting. The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Slide deck entitled Ampreloxetine KOL Event 104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE BIOPHARMA, INC. Date: December 8, 2025 By: /s/ Aziz Sawaf Aziz Sawaf Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.